Oncimmune Holdings plc Notice of Full Year Results

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced that it has been awarded the Queen’s Award for Enterprise 2022 in the innovation category, endorsing Oncimmune as a leading developer of applied immunodiagnostics for

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, today announced the signing of two new ImmunoINSIGHTS commercial contracts. The first contract is with an US-based clinical-stage biopharmaceutical company which is developing first-in-class cellular immunotherapies for cancer

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the signing of a new commercial follow-on contract with a world-leading medical research organisation based in the US, to validate the findings from a previous

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the signing of a commercial contract with a new top 10 global pharmaceutical company by revenue, initially focusing on the autoantibody profiling of Chronic Inflammatory Demyelinating Polyradiculoneuropathy.

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the signing of a go-to-market partnership with Synexa Life Sciences BV, a global leader in biomarker and bioanalytical science, focused on delivering a range of biomarker

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced its unaudited interim results for the six months ended 30 November 2021. Financial highlights ·     Recognised revenue for the period was £1.43M (H1 2020: £1.83M) was

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the signing of a new commercial contract with Verily Life Sciences LLC, an Alphabet company (parent company to Google), focusing on the autoantibody profiling of patients

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has stated today that it will be announcing its half year results for the six months ended 30 November 2021 on 28 February 2022. ImmunoINSIGHTS Service Business Oncimmune

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the publication of a paper entitled: “Paradoxical sex-specific patterns of autoantibody response to SARS-CoV-2 infection” 1 arising from the research collaboration between Oncimmune and Cedars-Sinai Medical Center

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced that the Company has signed further commercial contracts within its ImmunoINSIGHTS pharma services business. MSA and Commercial Contract Signed with Leading Global Pharmaceutical Company Following

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, today provided an update on commercial activity within its ImmunoINSIGHTS pharma services business. As we highlighted in the full year results announcement released on 2 November 2021, the

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, will be announcing its full year results for the year ended 31 May 2021 on Tuesday, 2 November 2021. Analyst and investor presentations Dr Adam M Hill,

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced it has signed an autoantibody profiling agreement with a leading global pharmaceutical company to evaluate the autoantibody profiles of patient samples in various autoimmune diseases. The

Oncimmune Holdings plc (LON:ONC), the leading global immunodiagnostics group, has announced the pre-publication of the three-year follow-up data for the Early detection of Cancer of the Lung Scotland trial in medRxiv titled ‘Targeted screening for lung